Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion
Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...
Company
Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...
Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies
According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment
UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...
AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...
Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025
Germany-based Fresenius Medical Care (FRA: FMEA) released its 2025 Q1 financial report, showing total revenues...
Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME
China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
Beijing Wantai’s HIV Urine Self-Test Kit Gains WHO Prequalification
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its HIV urine...
Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...
Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA
China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...
Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...